By Adriano Marchese

Gilead Sciences Inc. said Thursday that the European Medicines Agency has validated a marketing authorization application for its drug in the treatment of advanced breast cancer.

The biopharmaceutical company said the application for its drug sacituzumab govitecan-hziy is now under accelerated review by the agency. Gilead said the drug is of major interest for public health and therapeutic innovation.

"The validation of our EU marketing application is an important step toward addressing the significant unmet medical need for people with metastatic triple-negative breast cancer," Chief Medical Officer Merdad Parsey said.

Write to Adriano Marchese at adriano.marchese@wsj.com

(END) Dow Jones Newswires

03-25-21 1636ET